Mark R. Stein

2.9k total citations
66 papers, 2.2k citations indexed

About

Mark R. Stein is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Mark R. Stein has authored 66 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Immunology, 26 papers in Hematology and 16 papers in Genetics. Recurrent topics in Mark R. Stein's work include Immunodeficiency and Autoimmune Disorders (34 papers), Platelet Disorders and Treatments (23 papers) and Blood disorders and treatments (15 papers). Mark R. Stein is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (34 papers), Platelet Disorders and Treatments (23 papers) and Blood disorders and treatments (15 papers). Mark R. Stein collaborates with scholars based in United States, Austria and Germany. Mark R. Stein's co-authors include Lucielle Mansfield, Richard L. Wasserman, Isaac Melamed, Joseph A. Church, Harold S. Nelson, Heinz Leibl, Michael Borte, Scott Serels, Johann Sellner and Lyndon E. Mansfield and has published in prestigious journals such as Annals of Internal Medicine, American Journal of Respiratory and Critical Care Medicine and PEDIATRICS.

In The Last Decade

Mark R. Stein

65 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark R. Stein United States 26 802 649 623 619 559 66 2.2k
M M Henry United Kingdom 40 474 0.6× 589 0.9× 311 0.5× 3.5k 5.6× 510 0.9× 90 5.7k
Liza McCann United Kingdom 23 424 0.5× 91 0.1× 327 0.5× 476 0.8× 371 0.7× 62 2.1k
Jan Tore Gran Norway 40 1.1k 1.4× 76 0.1× 918 1.5× 345 0.6× 468 0.8× 110 4.6k
Francesco Zulian Italy 42 845 1.1× 38 0.1× 843 1.4× 827 1.3× 1.4k 2.4× 170 4.9k
Bianca Lang Canada 26 314 0.4× 85 0.1× 222 0.4× 434 0.7× 602 1.1× 79 2.2k
Carol B. Lindsley United States 25 239 0.3× 108 0.2× 148 0.2× 211 0.3× 662 1.2× 54 2.1k
Johannes‐Peter Haas Germany 27 502 0.6× 55 0.1× 120 0.2× 243 0.4× 873 1.6× 183 2.3k
Sampath Prahalad United States 32 701 0.9× 47 0.1× 136 0.2× 365 0.6× 1.4k 2.6× 116 2.6k
D. G. I. Scott United Kingdom 18 285 0.4× 266 0.4× 1.2k 1.9× 325 0.5× 99 0.2× 40 2.2k
Berit Flatø Norway 34 351 0.4× 88 0.1× 78 0.1× 571 0.9× 1.5k 2.7× 103 3.1k

Countries citing papers authored by Mark R. Stein

Since Specialization
Citations

This map shows the geographic impact of Mark R. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Stein more than expected).

Fields of papers citing papers by Mark R. Stein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Stein. The network helps show where Mark R. Stein may publish in the future.

Co-authorship network of co-authors of Mark R. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Stein. A scholar is included among the top collaborators of Mark R. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Stein. Mark R. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wasserman, Richard L., Isaac Melamed, Mark R. Stein, et al.. (2016). Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. Journal of Clinical Immunology. 36(6). 571–582. 41 indexed citations
2.
Suez, Daniel, Mark R. Stein, Sudhir Gupta, et al.. (2016). Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. Journal of Clinical Immunology. 36(7). 700–712. 48 indexed citations
3.
Stein, Mark R.. (2012). USE OF SUBCUTANEOUS IgG IN PATIENTS ON CONCOMITANT ANTICOAGULANT AND ANTIPLATELET THERAPY. 2 indexed citations
4.
Stein, Mark R., et al.. (2011). Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases. Postgraduate Medicine. 123(5). 186–193. 22 indexed citations
5.
Wasserman, Richard L., Isaac Melamed, Robert P. Nelson, et al.. (2011). Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency. Clinical Pharmacokinetics. 50(6). 405–414. 57 indexed citations
6.
Wasserman, Richard L., Isaac Melamed, Lisa Kobrynski, et al.. (2011). Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease. Journal of Clinical Immunology. 31(3). 323–331. 64 indexed citations
7.
Sleasman, John W., et al.. (2010). Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates. Journal of Clinical Immunology. 30(3). 442–448. 16 indexed citations
8.
Berger, Melvin, et al.. (2009). Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency. Journal of Clinical Immunology. 30(2). 321–329. 25 indexed citations
9.
Wasserman, Richard L., Joseph A. Church, Hans Peter, et al.. (2009). Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. European Journal of Pharmaceutical Sciences. 37(3-4). 272–278. 43 indexed citations
10.
Ballow, Mark, Luigi D. Notarangelo, Bodo Grimbacher, et al.. (2009). Immunodeficiencies. Clinical & Experimental Immunology. 158(Supplement_1). 14–22. 46 indexed citations
11.
Stein, Mark R., Robert P. Nelson, Joseph A. Church, et al.. (2008). Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies. Journal of Clinical Immunology. 29(1). 137–144. 81 indexed citations
12.
Church, Joseph A., Heinz Leibl, Mark R. Stein, et al.. (2006). Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency. Journal of Clinical Immunology. 26(4). 388–395. 64 indexed citations
13.
Stein, Mark R.. (2003). Possible mechanisms of influence of esophageal acid on airway hyperresponsiveness. The American Journal of Medicine. 115(3). 55–59. 68 indexed citations
14.
Lang, David M., Paul Visintainer, William C. Howland, Mark R. Stein, & Manuel Villareal. (2000). Survey of the extent and nature of care for adults and older adults by allergy/immunology practitioners. Annals of Allergy Asthma & Immunology. 85(2). 106–110. 3 indexed citations
15.
Serels, Scott & Mark R. Stein. (1998). Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourology and Urodynamics. 17(1). 31–36. 55 indexed citations
16.
Stein, Mark R., M Koenigsberg, & Maozhen Han. (1996). US case of the day. Adult-type granulosa cell tumor. Radiographics. 16(1). 200–203. 8 indexed citations
17.
Stein, Mark R.. (1995). Simplifying the Diagnosis and Treatment of Gastroesophageal Reflux and Airway Diseases. Journal of Asthma. 32(3). 167–172. 4 indexed citations
18.
Taub, Harvey C. & Mark R. Stein. (1994). Bladder distention therapy for symptomatic relief of frequency and urgency: A ten-year review. Urology. 43(1). 36–39. 7 indexed citations
19.
Stein, Mark R., Eliahu Laor, Bhupendra M. Tolia, & Roberto E. Reid. (1993). Unusual case of renal candida fungus balls. Urology. 41(1). 49–51. 5 indexed citations
20.
Stein, Mark R., et al.. (1989). Fatal portuguese man-o'-war (Physalia physalis) envenomation. Annals of Emergency Medicine. 18(3). 312–315. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M M Henry Breakdown of academic impact, for papers by Liza McCann Breakdown of academic impact, for papers by Jan Tore Gran Breakdown of academic impact, for papers by Francesco Zulian Breakdown of academic impact, for papers by Bianca Lang Breakdown of academic impact, for papers by Carol B. Lindsley Breakdown of academic impact, for papers by Johannes‐Peter Haas Breakdown of academic impact, for papers by Sampath Prahalad Breakdown of academic impact, for papers by D. G. I. Scott Breakdown of academic impact, for papers by Berit Flatø
Rankless by CCL
2026